<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428983</url>
  </required_header>
  <id_info>
    <org_study_id>HELPD V4 20191120</org_study_id>
    <nct_id>NCT04428983</nct_id>
  </id_info>
  <brief_title>The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease</brief_title>
  <official_title>The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson disease (PD) is considered a multisystemic neurodegenerative disorder, together
      with the classic motor disability, and a number of non-motor symptoms (NMS).NMS have a
      significant negative relation with patients' quality of life. In general, both medicinal and
      nonmedicinal therapies are often advised for PD patients with NMS, but robust evidences for
      underpinning the clinical effects are limited. Recently, the search for small preventative
      neurotrophic compounds that are responsible for the maintenance, survival of neurons has
      attracted much attention. Erinacine A, which is extracted from Hericium erinaceus is the one
      showed prominent beneficial effects in the central nervous system. It can increase NGF and
      catecholamine content in the locus coeruleus and hippocampus of rats. This markedly increases
      neuronal survival in different brain areas and substantially improve behavioral outcomes in
      various animal models. In a MPTP-induced Parkinsonism model, treatment with Hericium
      erinaceus mycelium reduced the loss of dopaminergic cell, eliminated neuronal apoptosis and
      reversed MPTP-associated motor deficits. Thus, this project intends to hold a randomized,
      controlled trial to assess the effect of Hericium erinaceus mycelium, which is enriched of
      Erinacine A, in NMS of PD. This project will enroll 80 patients with PD. Subjects will be
      randomly allocated into study or placebo group. Subjects will take Hericium erinaceus
      mycelium for 2 years (one capsule per meal per day) and their treatments for PD will not be
      altered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        1. PD patients aged 50-79 years diagnosed by neurologist (should exclude vascular
           parkinsonism, secondary parkinsonism( including toxin, drug, heavy metal, CO
           intoxication), normal pressure hydrocephalus, multiple system atrophy, progressive
           supranuclear palsy, cortical basal degeneration, dementia with Lewy Body, hereditary
           parkinson's disease with genetic mutation, Huntington's disease, Wilson disease, spinal
           cerebellar ataxia with extrapyramidal syndrome, essential tremor, dystonia)

        2. PD at Hoehn and Yahr stage 2-2.5

        3. without cognitive decline

      Exclusion criteria:

        1. with diabetes mellitus (DM)

        2. with nephropathy (GFR &lt; 30ml/min)

        3. with significant neurological deficits caused by vascular insults

      Measurement parameters:

        1. At recruitment: blood sugar, AST, ALT, BUN, Crea, Ca, Na, K and peripheral blood cell
           (for the expression levels of KATP)

        2. every 6 months: motor symptoms: UPDRS, evaluate with UDYSRS if presence with dyskinesia
           Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D,
           BPRS

        3. every 1 year: CASI, tilting table, AST, ALT, BUN, crea, Na, K, Ca

      Protocol:

      0 month (initial baseline):

        1. blood sugar, AST, ALT, BUN, Crea, Ca, Na, K and peripheral blood cell

        2. Tilting table test (autonomic function)

        3. CASI cognitive test

        4. UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report:
           PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS

        5. stool microbiota

      6 months: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms:
      self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS

      12 months:

        1. UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report:
           PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS

        2. CASI cognitive test, tilting table, AST, ALT, BUN, crea, Na, K, Ca

      18 months: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms:
      self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS

      24 months:

        1. UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report:
           PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS

        2. CASI cognitive test, tilting table, AST, ALT, BUN, crea, Na, K, Ca

        3. stool microbiota
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>baseline</measure>
    <time_frame>0 month</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1st</measure>
    <time_frame>6 momths</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2nd</measure>
    <time_frame>12 months</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3rd</measure>
    <time_frame>18 months</time_frame>
    <description>UPDRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>final</measure>
    <time_frame>24 months</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Hericium erinaceus mycelium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hericium erinaceus capsules 1 table tid orally per day for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules 1 table tid orally per day for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hericium erinaceus mycelium</intervention_name>
    <description>Hericium erinaceus capsules 3 tables per day for 24 months</description>
    <arm_group_label>Hericium erinaceus mycelium</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic PD patients, aged 50-79 years

          -  modified Hoehn &amp; Yahr stage 2-2.5

          -  Without subjective and objective cognitive decline (objective cognitive decline will
             be determined by CASI)

        Exclusion Criteria:

          -  With diabetes

          -  With end stage renal disease under hemodialysis

          -  With significant vascular insults that resulted in significant neurological deficits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Ya Lee</last_name>
    <role>Study Director</role>
    <affiliation>Bioengineering Center, Grape King Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Ya Lee</last_name>
    <phone>+886-3-4572525</phone>
    <phone_ext>2995</phone_ext>
    <email>ly.lee@grapeking.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan-Ting Sun, MD PhD</last_name>
      <phone>+886-6-2353535</phone>
      <email>ytsun@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Yuan-Ting Sun</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease, non-motor symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

